Is it Worth Retaining ResMed Stock in Your Portfolio Now?

ResMed (RMD) is experiencing growth, driven by strong mask sales (up 11% year-over-year globally in the recent quarter) and advancements in digital health technology, with a 15.1% surge in share price over the past year, outperforming both the industry and the S&P 500; however, macroeconomic headwinds, including the Middle East conflict and inflationary pressures, along with a competitive market, pose challenges to maintaining profitability, despite a 0.3% upward revision in fiscal 2025 earnings estimates to $9.48 per share.

Analysis

ResMed Inc. (RMD) has demonstrated robust financial performance, evidenced by a 15.1% share price appreciation over the past year, outperforming its industry's 8.6% growth and the S&P 500's 10.1% rise. This growth is largely attributed to its Mask business, which reported an 11% year-over-year global revenue increase in the third quarter of fiscal 2025, boosted by strong demand including a 13% rise in the United States, Canada, and Latin America, and benefiting from a competitor's product recall. Successful product launches, such as the AirFit F40 and AirTouch N30i, alongside advancements in digital health technologies like the cloud-based AirView and myAir platforms with AI-driven capabilities, are significant contributors to overall revenue growth. ResMed has consistently surpassed earnings estimates over the past four quarters, with an average surprise of 4.23%, and maintains an earnings yield of 3.9%, well above the industry average of 0.5%. However, the company faces challenges from a difficult macroeconomic landscape, including the Middle East conflict and persistent inflationary pressures, which have led to increased operating costs, with SG&A expenses rising 6.7% and R&D expenses up 8.9% year-over-year. Fierce competition in the sleep-disordered breathing market also presents an ongoing risk. Despite these headwinds, the Zacks Consensus Estimate for fiscal 2025 earnings has been revised upwards by 0.3% to $9.48 per share, with anticipated revenues of $5.12 billion, suggesting a 9.3% increase from the previous year, reflecting a generally positive outlook despite the challenges.

Key Decisions for Investors

• Given ResMed's strong performance in its Mask business, consistent earnings beats, and positive fiscal 2025 projections, investors may find it worthwhile to retain existing positions or consider new ones, particularly as the company is rated Zacks Rank #3 (Buy).
• Investors should carefully monitor the impact of macroeconomic headwinds, foreign currency fluctuations, and inflationary pressures on ResMed's operating margins, as evidenced by the recent 6.7% rise in SG&A and 8.9% increase in R&D expenses.
• The ongoing success of new product introductions, such as the AirFit F40 and AirTouch N30i, and the continued adoption of its digital health solutions will be critical indicators for sustaining growth momentum and navigating the competitive landscape.